| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1347 | 2018 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The Lancet Gastroenterology & Hepatology 2 (5), 325-336, 2017 | 291 | 2017 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 182 | 2022 |
| Barriers in access to healthcare services for chronic patients in times of austerity: an empirical approach in Greece II Kyriopoulos, D Zavras, A Skroumpelos, K Mylona, K Athanasakis, ... International journal for equity in health 13 (1), 1-7, 2014 | 93 | 2014 |
| Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications I Petrakis, IJ Kyriopoulos, A Ginis, K Athanasakis Expert review of pharmacoeconomics & outcomes research 17 (2), 165-180, 2017 | 69 | 2017 |
| Measuring the efficiency of the Greek rural primary health care using a restricted DEA model; the case of southern and western Greece N Oikonomou, Y Tountas, A Mariolis, K Souliotis, K Athanasakis, ... Health care management science 19 (4), 313-325, 2016 | 62 | 2016 |
| Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital J Parissis, K Athanasakis, D Farmakis, N Boubouchairopoulou, C Mareti, ... International journal of cardiology 180, 46-49, 2015 | 52 | 2015 |
| Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study M Geitona, H Kousoulakou, M Ollandezos, K Athanasakis, ... Annals of General Psychiatry 7, 1-12, 2008 | 41 | 2008 |
| The recent and projected public health and economic benefits of cigarette taxation in Greece HR Alpert, CI Vardavas, FJ Chaloupka, A Vozikis, K Athanasakis, ... Tobacco control 23 (5), 452-454, 2014 | 39 | 2014 |
| Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for … K Athanasakis, I Petrakis, E Karampli, E Vitsou, L Lyras, J Kyriopoulos BMC neurology 13, 1-7, 2013 | 39 | 2013 |
| Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost K Athanasakis, M Ollandezos, A Angeli, A Gregoriou, M Geitona, ... Diabetic Medicine 27 (6), 679-684, 2010 | 39 | 2010 |
| Cost-effective osteoporosis treatment thresholds in Greece P Makras, K Athanasakis, N Boubouchairopoulou, S Rizou, ... Osteoporosis international 26, 1949-1957, 2015 | 38 | 2015 |
| Going up in ashes? Smoking-attributable morbidity, hospital admissions and expenditure in Greece K Tsalapati, CI Vardavas, K Athanasakis, E Thireos, A Vozikis, E Pavi, ... The European Journal of Public Health 24 (3), 477-479, 2014 | 31 | 2014 |
| Subjective social status, social network and health disparities: empirical evidence from Greece A Charonis, II Kyriopoulos, M Spanakis, D Zavras, K Athanasakis, E Pavi, ... International Journal for Equity in Health 16 (1), 40, 2017 | 30 | 2017 |
| Clinical and financial burden of active lupus in Greece: a nationwide study G Bertsias, E Karampli, P Sidiropoulos, I Gergianaki, A Drosos, L Sakkas, ... Lupus 25 (12), 1385-1394, 2016 | 27 | 2016 |
| Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements N Boubouchairopoulou, N Karpettas, K Athanasakis, A Kollias, ... Journal of the American Society of Hypertension 8 (10), 732-738, 2014 | 26 | 2014 |
| Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece K Athanasakis, M Igoumenidis, E Karampli, E Vitsou, G Sykara, ... Clinical therapeutics 34 (8), 1803-1814, 2012 | 25 | 2012 |
| Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions T Balasopoulos, A Charonis, K Athanasakis, J Kyriopoulos, E Pavi Health policy 121 (3), 265-272, 2017 | 21 | 2017 |
| Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals I Gountas, V Sypsa, G Papatheodoridis, K Souliotis, K Athanasakis, ... World Journal of Gastroenterology 25 (11), 1327-1340, 2019 | 20 | 2019 |
| Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular … K Athanasakis, V Fragoulakis, V Tsiantou, P Masaoutis, N Maniadakis, ... Clinical therapeutics 34 (2), 446-456, 2012 | 20 | 2012 |
